Can umbralisib bring PI3Kδ out of the shadows?
- 1 April 2018
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 19 (4) , 432-434
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyThe Lancet Oncology, 2018
- Chronic lymphocytic leukaemiaNature Reviews Disease Primers, 2017
- Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignanciesBlood, 2017
- Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceBlood, 2016
- Targeted therapies in CLL: mechanisms of resistance and strategies for managementBlood, 2015
- Management of adverse events associated with idelalisib treatment: expert panel opinionLeukemia & Lymphoma, 2015
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2014
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent LymphomaNew England Journal of Medicine, 2014
- CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBlood, 2011